Get the Stockscreener App
2.01
1.47%
-0.03
Immuron Limited Adr stock is traded at $2.01, with a volume of 2,816.
It is down -1.47% in the last 24 hours and down -1.93% over the past month.
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
See More
Previous Close:
$2.04
Open:
$1.99
24h Volume:
2,816
Relative Volume:
0.24
Market Cap:
$11.46M
Revenue:
$2.35M
Net Income/Loss:
$-2.56M
P/E Ratio:
-4.4856
EPS:
-0.4481
Net Cash Flow:
-
1W Performance:
-6.94%
1M Performance:
-1.93%
6M Performance:
-15.19%
1Y Performance:
+14.20%
1-Day Range:
$1.99
$2.14
1-Week Range:
$1.96
$2.15
52-Week Range:
$1.65
$5.96
Immuron Limited Adr Stock (IMRN) Company Profile
Compare IMRN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMRN
Immuron Limited Adr
|
2.01 | 11.46M | 2.35M | -2.56M | 0 | -0.4481 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Immuron Limited Adr Stock (IMRN) Latest News
Immuron: Targeted oral antibodies to treat infectious diseases - Innovation News Network
Immuron Travelan® continued strong sales growth - GlobeNewswire Inc.
Immuron to Present at Q4 Virtual Investor Summit: Gut Disease Pipeline Showcase | IMRN Stock News - StockTitan
Immuron Travelan® continued strong sales growth - Quantisnow
NMRC Reports Results for Campylobacter Controlled Human Infection Model Study - The Manila Times
IMRNImmuron Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan
Immuron: US FDA provides favourable feedback ahead of investigational new drug application for IMM-529 - Proactive Investors Australia
Immuron Plans Phase 2 Trial for IMM-529 following FDA review - Markets Insider
Immuron Plans Phase 2 Trial for IMM-529 following FDA review | Daily Guardian - Daily Guardian Canada
Immuron secures new US DoD research award - Investing.com
Immuron secures new US DoD research award By Investing.com - Investing.com Australia
Why PriceSmart Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket - Markets Insider
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.34% - Investing.com India
Immuron Limited Announces Participation in the LD Micro Invitational XIII - The Kingston Whig-Standard
Immuron US DoD Naval Medical Research Center responds to - GlobeNewswire
Immuron Surges On U.S. DoD Funding For Travelan Research By Investing.com - Investing.com Nigeria
Immuron US DoD Naval Medical Research Center Receives feedback on IND Application for New Campylobacter ETEC Therapeutic - StockTitan
Immuron’s Technology Platform of Treatments in the Age of the Coronavirus Outbreak - GlobeNewswire
Immuron Limited Trade Ideas — NASDAQ:IMRN - TradingView
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.33% - Investing.com
Immuron Limited Issues Correction to Misleading Halt Announcement Headline - GlobeNewswire
Pharma & Biotech - Proactive Investors USA
Immuron Limited Adr Stock (IMRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):